Cancer-Killing virus trial launches for Hard-to-Treat tumors
NCT ID NCT05914376
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a modified virus called hV01 in 24 adults with advanced solid tumors that have not responded to standard treatments. The virus is injected directly into tumors and is designed to kill cancer cells while also boosting the immune system. The main goals are to check safety, find the right dose, and see how the virus behaves in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
a modified vaccinia virus (hV01) that carries a human immune-boosting protein (IL-21)
What this could lead to
If it works, this could point toward a new way to shrink advanced solid tumors by using a virus to attack cancer cells and boost the immune system.
What could go wrong
This is a very early (Phase 1) trial with only 24 people, so it is mainly checking safety. The virus may not work well in all patients, and side effects could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
-
Zhejiang People's Hospital
Hangzhou, Zhejiang, China